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1. Introduction 
Hypoglycemia is a common syndrome. The manifestations of hypoglycemia are nonspecific, 
vary among individuals and may change from time to time in the same individual. They are 
also typically episodic. Thus, although the clinical history is of fundamental importance in 
suggesting the possibility of hypoglycemia, the diagnosis cannot be made solely on the basis 
of symptoms and signs.  
The vast majority of instances hypoglycemia is secondary to treatment of diabetes. Only a 
minority of the cases are due to other relatively unfrequent causes. In practice, the most 
common initial questions are whether the patient truly has hypoglycemia, and if it is likely 
to be reactive or whether there are grounds for considering insulinoma or islet hyperplasia.  
The clinical and physiopathological features, diagnosis and treatment of pancreatic beta cell 
tumors will be discussed in the following chapter.  
2. Historical data 
Low blood glucose concentrations were first described in the 19th century as a feature of 
several diseases. The islets of Langerhans were discovered in 1869 and were named after the 
German pathologist Paul Langerhans who discovered regions within the pancreas that 
produced hormones. Nicholls first described in the findings of an autopsy an islet cell tumor 
in 1902. In 1922 Banting and Best discovered insulin; however, it was not until insulin 
became available for the treatment of diabetes mellitus in the early 1920s that clinical events 
similar to those arising from overtreatment with insulin were identified in nondiabetic 
patients. In 1923, Campbell and Fletcher were the first to describe the hypoglycemic 
complex due to an insulin excess in non-diabetic patients. 
The first resection of an insulinoma was performed in 1927, when WJ Mayo removed an 
insulin-secreting tumor from a physician and injected it into rabbits that developed 
subsequently hypoglycemia. In 1938, Whipple reported a triad, considered pathognomonic 
for insulinoma: blood glucose levels less than 50 mg/dL, neurologic symptoms of 
hypoglycemia and immediate alleviation of symptoms after glucose ingestion. In 1954, 
Wermer described a family with a syndrome often associated with pancreatic and  
other neuroendocrine tumors, the multiple endocrine neoplasia type 1 (MEN1). In 1993,  
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Gagner et al. reported the first successful laparoscopic distal pancreatectomy and 
pancreatoduodenectomy. The first successful laparoscopic resection for pancreatic 
insulinoma was made in 1996. 
3. Clinical spectrum of pancreatic beta cell tumors 
Pancreatogenous hypoglycemia is a syndrome characterized by endogenous hyperinsulinemic 
hypoglycemia that comes from a pancreatic beta-cell malfunction. This malfunction can exist 
as a tumoral mass or a hyperplasia. 
Pancreatic beta-cell tumors usually appear as a well-defined mass producing insulin named 
insulinoma. Commonly insulinomas are sporadic although a low percentage of them are 
associated with inherited diseases. Another small percentage are not tumoral, but a 
hyperplasia of beta cells or nesidioblastosis which develop a similar syndrome to 
insulinomas but with different pathological appearance and therapeutic management.  
3.1 Sporadic insulinoma 
Insulinomas are so rare that few institutions have accrued enough experience to provide 
meaningful data regarding epidemiological or demographic characteristics. The estimated 
incidence of insulinomas in the general population is estimated 1-4 per 1,000,000 yearly. 
However, the incidence has been reported higher in autopsy studies (0.8-10%), suggesting 
that these tumors frequently remain undiagnosed. The mean age of patients at presentation 
is between 47-50 years, patients with MEN 1 are usually younger. In most series, females 
show a discrete predominance over men (ratio 1.5-1:1).  
Insulinomas comprise 70% to 80% of all functional neuroendocrine pancreatic tumors. The 
majority are solitary, benign lesions occurring in a sporadic setting; they are also single , 
small and hypervascular, with 90% measuring less than 2 cm and 30% measuring less than 1 
cm in diameter; approximately 10% are multiple.  
Malignant insulinomas represent about 10% of all insulinomas. Contrary to benign ones, 
malignant are more frequent in men. 
Insulinomas have a lower malignancy rate than other islet cell tumors such as gastrinomas 
and glucagonomas. It is very difficult to distinguish between malignant and benign 
insulinomas since endocrine tumors show frequently mild nuclear and structural atypia. 
Moreover, malignant insulinomas are usually diagnosed intrasurgically or by an image 
evidencing liver metastases, regional nodes or local invasion.  
However, malignant insulinomas, which are solitary and have no evidence of metastases, 
usually have a better prognosis. Several studies have been performed to investigate the 
mean survival of a metastatic insulinoma that has been established in 2.6 years since 
diagnosis (1.6-7.5) (Starke et al., 2005). 
3.2 Multiple endocrine neoplasia type 1 
Multiple endocrine neoplasia type 1 is an autosomal dominant predisposition to tumors of 
the parathyroid glands, pancreatic islet cells and anterior pituitary; hence the mnemonic 
device of the “3 Ps”. However, the clinical spectrum of this disorder has been expanded.  
A consensus statement from an international group of endocrinologists recommends that 
MEN1 is defined as the presence of two of the three main MEN1 tumor types (parathyroid, 
entero-pancreatic endocrine adenomas, and pituitary adenomas). Familial MEN 1 is defined 
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as an index MEN1 case with at least one relative who has one of the three main MEN1 
tumors. (Brandi, ML et al, 2001) 
Effective treatment is usually available for hyperparathyroidism and pituitary disease; the 
malignant potential of pancreatic endocrine tumors is the primary life-threatening 
manifestation of MEN1. Functioning pancreatic islet cell or gastrointestinal endocrine cell 
tumors become clinically apparent in approximately one third of patients with MEN1. The 
most common cause of symptomatic disease is the Zollinger-Ellison (gastrinoma) syndrome 
(ZES), leading to multiple peptic ulcers. Symptomatic insulinomas also occur with moderate 
frequency, while VIPomas and glucagonomas are rare. 
Insulin-producing pancreatic islet cell adenomas in MEN1 represent about 10% of the 
totality of insulinomas. They are often small, may be multiple, and may be associated with 
the simultaneous presence of other islet cell tumors. The diagnosis of insulinoma depends, 
as in nonfamilial causes, upon the documentation of hypoglycemia with characteristic 
symptoms that are rapidly reversed by the administration of glucose, and inappropriately 
high serum insulin concentrations. 
Approximately 4 to 10 percent of patients with insulinoma have MEN1, and in most of them 
the MEN1 is known or suspected. Treatment is complicated in these patients by the possible 
presence of multiple insulinomas, the likelihood that preoperative or intraoperative location 
techniques may miss small tumors and the continuing risk of recurrence of pancreatic 
tumors after surgery. As a result, some experienced surgeons recommend local excision of 
any tumors found in the head of the pancreas plus a distal subtotal pancreatectomy. This 
approach differs from that in patients with sporadic insulinomas, who typically have a 
solitary tumor and in whom the localization and local excision alone are usually successful. 
In a cohort study of therapeutical response, patients who required additional surgical 
treatment because of failed initial surgery or recurrence of insulinoma over the period 1927 
to 1986 had an increased prevalence of MEN 1 with multiple tumors (25 %) and malignant 
insulinomas (13 %).(Service, FJ, et al. 1991) 
The inheritance of classical MEN1 follows an autosomal dominant pattern. Genetic linkage 
analysis implicated a region on the long arm of chromosome 11 (11q13) as the site of “MEN1 
gene” in 1988. In 1997 the candidate gene was found, the MEN 1 gene, whose protein 
product is termed “menin” was mutated in 14 of 15 families with MEN1.  
Much has been learned about the biochemical and cellular functions of menin, but the 
precise way in which these functions relate with the tumorigenesis is still not well 
established. However, it is clear that most of the MEN1 gene mutations found in MEN1 
patients would be expected to inactivate or disrupt menin function. 
3.3 Noninsulinoma pacreatogenous hypoglycemia or nesidioblastosis 
Noninsulinoma pancreatogenous hypoglycemia or nesidioblastosis is a syndrome 
characterized by endogenous hyperinsulinemic hypoglycemia that is not caused by an 
insulinoma which accounts for most cases of hyperinsulinemic hypoglycemia. 
Nesidioblastosis is the name given to the presence of islets in intimate association with 
ducts, leading to the formation of so-called ductulo-insular complexes.  
Nesidioblastosis has mainly been described in neonates. Since Harness et al first described 
nesidioblastosis in adults, it has been reported in association with other diseases, such as 
Zollinger-Ellison syndrome, multiple endocrine adenomatosis, β-cell adenomatosis, 
www.intechopen.com
 
Hypoglycemia – Causes and Occurrences 
 
190 
Lindau’s disease, bariatric surgery, cystic fibrosis, insulinomas, pancreatic transplantation, 
orbital lymphoma with hypopituitarism and adrenal insufficiency, familial adenomatous 
polyposis, hypergastrinemia, and pancreatic polypeptidemia.(Abellán, P., et al. 2008). 
Sporadic hyperinsulinemic hypoglycemia is the main clinical feature of nesidioblastosis and 
the diagnostic proceedings are the same as those of insulinoma. However, therapeutic 
management differs as the extension of the disease in the pancreatic gland may be diffuse. 
4. Pathogenesis 
Insulinomas are the most frequent functioning endocrine pancreatic tumors. The etiology of 
these kinds of tumors is poorly understood until the moment. Some tumors may harbor 
MEN 1 gene mutations, the susceptibility gene of the MEN 1 syndrome, but most cases 
show wild type MEN 1.  While those tumors originated in the exocrine pancreas have been 
attributed to environmental risk factors and certain mutations, in those from the endocrine 
pancreas the evidence is quite limited. 
In order to improve the diagnosis, prognosis and therapy of insulinoma patients, it is 
important to increase our understanding of the molecular processes underlying tumor 
development and progression. During tumorigenesis in general an alteration in the cell 
physiology takes place as a result of an accumulation of genetic alterations which lead to an 
uncontrolled cell growth, tissue invasion and metastatic spread. The knowledge of these 
molecular alterations permits us a focused molecular treatment in these tumors, especially 
in those with a greater malignant potential. 
Therefore, a brief revision of the possible alterations which lead to tumorigenesis in the 
sporadic insulinoma will be discussed. The altered cellular phenotype in these tumors may 
involve different genes and mutations which participate in self-sufficiency growth signals, 
insensitivity to growth-inhibitory signals, evasion of programmed cell death (apoptosis), 
unlimited replicative potential, sustained angiogenesis and tissue invasion. It is also 
important to consider that the mechanisms involving MEN 1 insulinoma development and 
sporadic insulinoma are not the same (Jonkers, JMH et al. 2007) (figure 1). 
4.1 Menin molecular interactions 
The MEN 1 gene was the first gene described as a candidate gene implicated in 
insulinoma tumorigenesis. Several studies have been performed which suggest a minor 
role for MEN 1 inactivation by mutation in human sporadic insulinomas. Menin, the 610 
aminoacid protein encoded by MEN1 has been found to partner in vitro with a variety of 
proteins that comprise transcription factors, DNA processing factors, DNA repair proteins 
and cytoskeletal proteins. The role of menin inactivation in tumorigenesis, which takes 
place in the MEN type 1, is diverse participating in mechanisms of failure in DNA repair 
(via FANCD2), transcription and proliferation (via p27/p18), switching growth 
suppression to growth proliferation (via JunD), functional stimulation of S-phase kinase 
and essential component for the S-phase entry, transcriptional activation of NFKB which 
inhibits apoptosis and stimulates cell growth or neutralizing cell growth inhibition 
through SMAD3. 
Although this inactivation only occurs rarely in sporadic insulinomas, studies which focus 
on the molecular alterations of menin interacting proteins should be developed.  
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Fig. 1. Signaling molecules and paths that may be involved in insulinoma tumorigenesis. 
The upper part (shaded in grey) represents those which participate in MEN 1 and the lower 
part (white) those in sporadic insulinoma. Those whose role have been suggested but not 
confirmed are in white, those with a loss of function are in grey and those with a gain are 
shaded. (Adapted from Jonkers, YMH. et al. 2007) 
4.2 Self-sufficiency in growth signals 
Cell cycle deregulation is one of the defining features of cancer. The roles of several proteins 
have been suggested to stimulate cell proliferation in insulinomas. 
Cyclin dependent kinase 4 (CDK4) together with its regulatory subunit cyclin D governs cell 
cycle progression through G1 phase. The deregulation of this complex has been studied in 
islet -cell proliferation. Several studies show that knock-in mice with an homozygous 
CDK4 mutation develop multiple neoplasia, most commonly endocrine tumors, including 
benign insulinomas. However, CDK4 mutations have not been detected in sporadic human 
insulinomas neither a significantly altered expression of CDK4. On the other hand, 
overexpression of cyclin D1 has been observed in benign insulinomas compared to normal 
pancreatic islets, suggesting that this oncogene is involved at least in the tumorigenesis in a 
certain subgroup of these tumors. 
The Akt 1 gene has also been described to induce -cell proliferation via CDK4 by increasing 
cyclin D1 and D2 levels. Transgenic mice which overexpress a constitutively active form of 
Akt 1 in islet beta cells exhibit striking increases in -cell mass, proliferation, cell mass and 
malignant tumor formation. The Akt 1 gene is located on a region which has often found to 
be gained in insulinomas of malignant behavior. One of the growth factors which seems to 
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trigger the PI3K/Akt pathway is the insulin-like growth factor receptor. Several components 
of the IGF system show differences in mRNA expression suggesting a prominent role of this 
system in growth promotion. This pathway has been extensively explored and is one of the 
molecular targets being used recently in malignant insulinomas. Everolimus is an orally 
derivative of rapamycin that inhibits Ser/Thyrosine kinase, the PI3k/Akt/mTOR pathway.  
A gene expression profiling study described the GNAS gene (guanine nucleotide binding 
protein alpha subunit) as the most highly expressed gene in insulinomas compared to normal 
pancreatic tissue. It is also well established that activating mutations of the gene encoding 
GNAS can stimulate proliferation of endocrine cells and are involved in the pathogenesis of 
several tumors. The underlying method of this up regulation is still unknown and until now 
no mutations of this gene have been identified in human insulinomas. 
TGF (transforming growth factor has been associated with the development of 
insulinomas. Immunohistochemistry showed its expression already in benign tumors and 
enhanced expression in malignant insulinomas. TGFsecreted by tumor cells can bind to 
the epidermal growth factor receptor (EGFR) leading to an autocrine activation of the Ras 
signaling pathway and putatively to its oncogenic activity. EGFR is located in chromosome 
7p12, gained in 8% of benign versus 89% of malignant insulinomas, thus, speculating an 
involvement in the malignant progression of insulinomas. 
Recent studies have also shown that gain of chromosome 9q is one of the earliest aberrations in 
insulinoma development. FISH analysis showed multiple copies of cAbl gene in these tumors 
including cases with amplification. cAbl tyrosine kinase gene is a proto-oncogene with growth 
promoting activity. Overexpression of cAbl by means of RT-PCR and inmuhistochemistry 
were found suggesting and early role in some subgroups of insulinomas. 
In conclusion, several proteins involved in self-sufficiency cell growth, including cyclin D, 
Akt 1, GNAS, TNF and cAbl have been suggested to stimulate cell proliferation in 
insulinomas, although their individual roles still remain elusive. 
4.3 Insensitivity to anti-growth signals 
Within a normal tissue, multiple antiproliferative signals operate to maintain cellular 
quiescence and tissue homeostasis. Cancer cells must evade these anti-proliferative signals if 
they are to prosper.  
At the molecular level, many antiproliferative routes are controlled by the retinoblastoma 
protein (pRb). In tumors with pRb inactivation as the basis of pathology somatic loss of one 
Rb allele commonly accompanies a point mutation or micro-deletion of the other allele. 
Deletion of Rb gene has so far been detected only in one human insulinoma. However, other 
mechanisms of inactivations of pRb are phosphorylation, but studies done until the moment 
conclude that pRB may not be strictly involved in de initiation of insulinomas. 
CDKN2 locus on chromosome 9p21 harbors tumor suppressor genes which restrain cell 
growth by affecting the function of pRb and p53. Downregulation of expression of 
CDKN2A/p16, CDKN2B/p15 and CDKN2D/p14 have been studied. Absence of expression 
of p15 was detected in 33% of benign insulinomas. On the other hand, a low frequency of 
alterations were detected in p16 but a down-regulation of p16 protein was detected and it is 
likely to be involved in insulinoma tumorigenesis. Two other inhibitors of CDK2, p21 and 
p27 have been studied. P27 was expressed in 88% of insulinomas, including malignant 
tumors but was also expressed in normal pancreatic islet cells. The strong expression of p21 
and p27 may explain the slow growth in a subset of tumors and suggests differences in 
tumorigenesis between MEN1-associated and sporadic insulinomas.  
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The Raf-1 kinase inhibitory peptide (RKIP) binds to Raf-1 and MEK in vivo and in vitro, 
thus interfering with the activation of the ERK signaling pathway, and plays an important 
role in the inhibition and beta-cell proliferation. Expression of RKIP was studied in 
insulinomas showing an absence of expression in comparison with normal islet cells. 
PTEN (phosphatase with tensin homology) is a potent negative regulator of the PI3K/Akt 
signaling pathway. The PTEN gene is located on chromosome 10q23 a region which is often 
lost in malignant insulinomas.  Loss of PTEN has been associated with malignancy of 
insulinomas, as it was not observed in benign insulinomas.  
In conclusion, evading antiproliferative signals, for example through inactivation of pRb, 
p15, p16 and/or PTEN may be important features involved in the development of 
insulinomas. 
4.4 Evading apoptosis 
The ability of tumor cell population to expand is not only determined by the rate of 
proliferation but also by the rate of cell death or apoptosis. Acquired resistance toward 
programmed cell death (apoptosis) is a hallmark of most types of cancer.  
Certain apoptotic factors such as BcI-2 have been studied, and are frequently expressed in 
gastroenteropancreatic neuroendocrine tumors which are usually slow-growing and less 
aggressive tumors, suggesting that in these tumors BcI-2 expression leads to indolent tumor 
growth. Another factor such as c-Myc  has also been demonstrated to induce highly 
malignant beta-cell tumors in mouse models. All this evidence suggests that suppression of 
apoptosis may contribute also to the initiation of these tumors.  
Survivin, a member of another family of apoptosis inhibitors is a protein that can suppress 
apoptosis and regulate cell division.  The gene encoding this protein, BIRC5, is located in 
chromosome 17q25 a region gained in one third of malignant insulinomas versus none of 
the benign insulinomas.  
The P73 gene, encodes a protein with similar function to p53, and might be an interesting 
candidate for insulinoma progression. It is located on chromosome 1p36, a region that is 
deleted in 44% of malignant insulinomas and associated with metastasic disease.  
In conclusion, due to the overall low proliferation rate in insulinomas, it is tempting to 
speculate that evasion of apoptosis is more important in their development instead of 
increased proliferation. 
4.5 Unrestricted replicative potential 
Human cells carry a cell-autonomous program that limits their multiplication. This program 
is independent from of the cell to cell signaling pathways. The progressive erosion of 
telomers during successive cycles of replication eventually causes cells to lose their ability to 
protect the ends of chromosomal DNA, which results letal to them.  
Telomere maintenance is evident in virtually all types of malignant cells. For this purpose 
the malignant cells up-regulate the expression of telomerase enzymatic activity. Also stem 
cells do have a high telomerase activity. Because pancreatic stem cells are suggested as the 
clonal origin of insulinomas, telomerase activity may be expected in these tumors. This fact 
has not been demonstrated in sporadic insulinomas, however, in MEN1-associated 
insulinomas may play an important role. 
On the other hand, telomeric loss has been shown by array to be associated with malignant 
behavior of insulinomas. In insulinomas with uncertain behavior telomeric losses were more 
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frequently observed than chromosomal instability. This suggests that telomeric loss occurs 
prior to and is causative of chromosomal instability during insulinoma tumorigenesis.  
These data indicate that escape from replicative senescence, which is expected to occur as a 
result of telomeric loss, is the basis of tumor progression.  
Therefore telomeric loss and chromosomal instability seem to accumulate during tumor 
progression and it is tempting to speculate that p16 down regulation and telomerase activity 
in addition ensure unrestricted replicative potential. Inactivation of menin may trigger 
activation of telomerase earlier in tumor development (MEN1). 
4.6 Sustained angiogenesis 
Tumorigenesis in general is critically dependent on the development of vascular supply. 
The fact that endocrine tumors are highly vascular in nature renders analysis of 
angiogenesis as a prognostic factor highly pertinent.  However, in contrast to other cancers, 
a high vessel density in endocrine pancreatic tumors was found to correlate with good 
prognosis as well as with hormone production.  
Endocrine pancreatic tumor cells overproduce the angiogenic peptide vascular endothelial 
growth factor (VEGF), which is likely to play an important role in the angiogenic process 
associated with endocrine tumorigenesis but they seem to lose this expression during tumor 
progression.  In conclusion, although activation of angiogenesis is not indicated in tumor 
progression, it will be necessary to study additional angiogenic factors that may substitute 
loss of blood supply in insulinomas. 
4.7 Markers to predict metastasic disease and clinical outcome in insulinomas 
Certain markers such as CK-19 are associated with malignancy. Immunostaining of CK19 
has resulted a reliable indicator of tumor-specific death in insulinomas. Also, chromosomal 
instability indentified by array has been detected as an optimal predictor of metastasic 
disease. Ki-67 ≥ 2% and p53 overexpression were found to be associated with malignancy in 
a few individual insulinoma cases.  
5. Histopathology  
Insulinomas exhibit four main histological patterns including: solid, trabecular, gland-like 
(tubular or acinar) and mixed forms. Larger tumors are encapsulated but the capsule is 
usually incomplete. Smaller tumors and microadenomas are rarely encapsulated. Tumor 
cells frequently exhibit a bland cytology and cells with large pleomorphic nuclei are rare. If 
present, these features are not predictive of malignant behavior. A relatively uncommon, 
but characteristic finding in insulinomas is the deposite of amyloid. Its major component is 
islet amyloid polypeptide or amylin that can be visualized by immunohistochemistry. 
Calcifications and intracytoplasmatic pigment may unfrequently be seen in insulinomas. 
(Figure 2) 
The majority of insulinomas exhibit immunoreactivity for insulin and proinsulin. 
Insulinomas without any positive staining for insulin are also found indicating that the 
produced insulin is not stored inside the cells, but immediately released. In such cases, 
proinsulin staining or insulin messenger RNA in situ hybridization are valuable 
alternatives, but rarely used and more costly. 
The byosinthesis of insulin takes place usually in the endoplasmic reticulum. In normal 
pancreatic beta-cells, proinsulin-insulin conversion occurs in acidic immature secretory 
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granules of the trans-Golgi apparatus. In contrast to beta-cells, the proinsulin-insulin 
conversion in insulinomas occurs already in the Golgi apparatus, but remains incomplete, 
resulting in the formation of secretory granules containing both proinsulin and insulin.. The 
distribution pattern of proinsulin and insulin has been investigated and no correlation was 
found between a particular staining pattern, histological type, multihormonality or the 
degree of malignancy of insulinoma. (De Lellis, et al.2004). 
Approximately 10-15% of insulinomas are classified as malignant on the basis of the 
presence of organ and/or lymph node infiltration or distant metastases. The most common 
sites of metastases for insulinomas are the peripancreatic lymph nodes with occasional 
hepatic metastases.  
According to the WHO criteria histopathologically pancreatic neuroendocrine tumors 
(including insulinomas) should be classified into four groups (Komminoth, P. et al, 2004):  
- Well differentiated endocrine pancreatic tumors in the absence of all adverse criteria 
- Well differentiated endocrine pancreatic tumors of uncertain behavior: tumor diameter 
> 2cm, >2 mitosis/10 high power fields, angioinvasion or a proliferative index Ki-67 > 
2%. 
- Well differentiated endocrine pancreatic carcinomas: gross local invasion or metastases. 
- Poorly differentiated pancreatic endocrine carcinomas: > 10 mitosis/ 10 high power 
field 
Because these criteria are not always reliable, markers have to be detected to predict a 
possible malignant outcome of insulinomas in an earlier stage. 
In the case of nesidioblastosis, the morphological criteria for establishing its diagnosis are 
the presence of differently-sized islets often with somewhat irregular outline, and 
irregularly sized and poorly defined endocrine cell clusters scattered in the acinar 
parenchyma and often intimately connected with small or large ducts (ductulo-insular 
complexes). Another feature is a distinct islet cell hypertrophy with nuclear enlargement, 
often resulting in the presence of giant and bizarre nuclei. Nesidioblastosis is classified into 
focal and diffuse types characterized by different clinical outcomes. Focal nesidioblastosis 
exhibits nodular hyperplasia of islet-like cell clusters, including ductuloinsular complexes 
and hypertrophied insulin cells with giant nuclei. In contrast, diffuse nesidioblastosis 
involves the entire pancreas with irregularly sized islets. (Figure 2) 
 
 
Fig. 2. Histopathological characteristics of insulinoma and nesidioblastosis. A. Insulinoma 
with peripancreatic fat. Haematoxylin and eosin (100x). B. Nesidioblastosis. Cluster of islets 
of varied size and shape in apposition to pancreatic ductules. Haematoxylin and eosin 
(250x). C. Insulin immunostaining showin insulinoma (right) with pancreatic tissue (100 x). 
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6. Clinical features 
Insulinoma patients characteristically present at diagnosis with symptoms of hypoglycemia, 
especially neuroglycopenic symptoms that may or may not be preceded by symptoms due 
to sympathetic overdrive. The leading symptoms establishing the diagnosis of endogenous 
hyperinsulinism are comprised in the Whipple’s triad. The neuroglycopenic symptoms of 
insulinomas include confusion, visual change, and unusual behavior. Neuroglycopenic 
symptoms are the direct result of central nervous system neuronal glucose deprivation. 
Neurogenic symptoms are the result of the perception of physiologic changes caused by the 
autonomic nervous system discharge triggered by hypoglycemia. Sympathoadrenal 
symptoms may include palpitations, diaphoresis and tremulousness. Amnesia for 
hypoglycemia is common in these patients. (Table 1) 
This common clinical manifestation takes place usually in a fasting state. However, 
postprandial hypoglycemia may be a feature or even the sole manifestation of hypoglycemia 
in some patients. In retrospective reviews done to patients with confirmed insulinoma, 21% 
reported fasting and postprandial symptoms and 6% reported only postprandial symptoms 
(Placzkowski, KA, et al. 2009). The hypoglycemia in patients with insulinoma is primarily 
due to reduced hepatic glucose output rather than increased glucose utilization.  
The mean duration of these symptoms before the diagnosis is established is less than 1.5 
years. However, a few patients can be symptomatic for decades and can be misdiagnosed 
with a neurologic or psychiatric disorder. Clinical manifestations of an insulinoma can 
mimick central nervous system disorders, like epilepsy. 
 
Adrenergic symptomatology Neuroglucopenic syptomatology 
Tremulousness 
Palpitations 
Anxiety 
Hunger 
Parestesias 
Hyperhidrosis/sweat 
 
Confusion
Letargy 
Headache 
Visual manifestations 
Fatigue, dizziness 
Difficulty to talk 
Unusual behavior 
Seizures 
Coma 
Death
Table 1. Hypoglycemic symptomatology. 
7. Diagnosis 
Neuroendocrine tumors (NETS) are rare, slow growing neoplasms characterized by their 
ability to store and secrete different peptides and neuroamines. Some of these substances 
cause specific clinical syndromes, whereas others may have elevated plasma or urine levels 
that are not associated with specific syndromes or symptom complexes. 
The biochemical markers are those hormones or amines secreted by the neuroendocrine 
cells from which these tumors are derived. In the case of the insulinoma, derived from the 
beta pancreatic cells, the biochemical marker secreted is insulin which leads in excess, to an 
hypoglycemic syndrome.  
The Whipple’s triad is the cornerstone for the suspicion of an insulinoma, although other 
causes must be ruled out. 
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WHIPPLE'S TRIAD 
 
1. Hypoglycemia symptoms induced by fasting 
 
2. Blood glucose       < 50 mg/dL + symptoms 
                                                   < 40 mg/dL regardless of symptoms 
 
3. Relief of symptoms when glucose is raised to normal 
Fig. 3. Whipple's triad 
Clinical syndrome is therefore the first step that leads to the suspicion of an insulinoma. 
7.1 Laboratory confirmation 
The diagnosis of an insulinoma can be established by determining plasma proinsulin, 
insulin, c-peptide and glucose levels, which are usually performed during a 72-hour fast. It 
is important to realize that insulin levels are increasingly being determined by 
immunochemiluminiscent assays or specific immunoradiometric assays that do not cross-
react with proinsulin and give lower values than that obtained with most insulin 
radioimmunoassay, which can affect the proposed criteria listed in many reviews for 
diagnosis, which were based on radioimmunoassay results. 
There are six main criteria for the diagnosis of insulinoma: documented blood glucose levels 
of 45 mg/dL or less (2.2 mmol/L), concomitant insulin levels of 6 U/mL or greater (≥ 36 
pmol/L; ≥ 3 U/mL), c-peptide levels 200 pmol/L or greater, proinsulin levels 5 pmol/L or 
greater, hydroxybutyrate levels 2.7 mmol/L or less and absence of sulfonylurea 
(metabolites) in the plasma and/or urine. (Table 2) 
 
Biochemical tests Confirmation of insulinoma 
Plasma glucose <45 mg/dL 
Insulin ≥ 3 U/mL 
C-peptide ≥ 200 pmol/L 
Proinsulin ≥ 5 pmol/L 
hydroxybutyrate < 2.7 mmol/L 
Table 2. Main criteria for the diagnosis of insulinoma 
Further controlled testing under supervision includes the 72-hour fast, which is the gold-
standard criterion for establishing the diagnosis of insulinoma. Actually, 98% of the patients 
with insulinoma will develop symptomatic hypoglycemia within 72 hours. When the 
patient develops symptoms and the blood glucose levels are < 40(45) mg/dL or less (<2.2 
mmol/L), blood should also be drawn for c-peptide, proinsulin and insulin, and the fast 
should be stopped. Failure in appropriate insulin suppression in the presence of 
hypoglycemia substantiates an autonomously secreting insulinoma.  
7.1.1 How to perform a fast test 
The 72-h fast test can be initiated at any hour and may be prolonged until 72-hours. It is 
important to date the onset of fast as well as the last ingestion of calories. During the whole 
test, the patient may only be allowed to drink calorie and caffeine free beverages. It is 
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important to ensure that the patient is active during waking hours and in some cases some 
exercise can be recommended at the end of the fast if it resulted negative.  
In the basal state with the initiation of the fast state a 6mL extraction for glucose, insulin and 
c-peptide will be done. These measurements should be repeated every 12 hours with a 
previous measurement of capillary glucose at 12, 24, 36, 48, 60 and 72 hours and after 
exercise if it takes place. 
The end of the fast will be when the patient presents signs and symptoms of hypoglycemia 
and plasma glucose is <40 mg/dL. In this moment blood glucose will be drawn as well as 
insulin and c-peptide. Hypoglycemia will not be reversed until the central laboratory 
confirms the glucose value or the patient is unconscious and has fits.  The reversal of the 
hypoglycemia will be with the administrations of oral glucose or intravenous if needed 
(dextrose 40% 250mL). 
At the end of the fast, a measurement of glucose, insulin, c-peptide and sulphonylurea 
screen (blood and urine spot), should be done. If the patient presents no symptoms during 
the fast, it can be finished with a 15-30 min exercise (for example brisk walk) around the 
hospital and re-measuring. 
7.1.2 Interpretation of a fast test 
90% of insulinomas will present hypoglycemia before 72 hour fast and insulin will be 
inappropriately high in relation with glucose levels.(Figure 4) 
 
 
Fig. 4. Plasmatic insulin and glucose limits after a fast in normal subjects and patients 
affected of an insulinoma. The black area represents the normal response to hypoglycemia. 
The striped area represents the usual response in patients affected of an insulinoma. 
(Redrawn from Service, FJ. et al, 1999). 
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Rare disorders, in which the biochemical findings simulate those of an insulinoma because 
they are also associated with endogenous hyperinsulinemia include administration of 
exogenous insulin or sulphonylureas and insulin autoimmune hypoglycemia. 
The fast test permits us to differ between insulinoma, exogenous administration of insulin 
and sulphonylureas administration. If this last is suspected, urine and plasma collection of 
sulphonylureas should be performed. (Table 3) 
 
 Insulin C-peptide Proinsulin Sulphonylureas 
 
Exogenous 
administration of 
insulin 
 
   
NEGATIVE 
Insulinoma 
 
 
 
  
NEGATIVE 
 
Exogenous 
administration of 
sulphonylureas 
 
   
POSITIVE 
Table 3. Differential diagnosis determined by the results of a fast test. 
Insulin autoimmune hypoglycemia occurs in patients who have antibodies directed to 
endogenous insulin or to the insulin receptor. Symptoms can occur postprandially, fasting, 
or in both states. In patients with insulin autoantibodies, insulin secreted in response to a 
meal binds to the antibody and then disassociates in an unregulated fashion causing 
hyperinsulinemia and hypoglycemia. In patients with antibodies to the insulin receptor, 
hypoglycemia occurs as a result of antibody activation of the receptor. The presence of 
insulin or insulin receptor antibodies can distinguish insulin autoimmune hypoglycemia 
from insulinoma. The antibodies do not have to be measured during an episode of 
hypoglycemia.  
7.1.3 48 hour versus 72 hour fast 
It has been proposed that the sensitivity of the 48h fasting test is between 94.5 and 95.7% 
and should be enough for the diagnosis of insulinoma instead of the 72-hour fast. In a series 
of 127 patients with insulinoma, the fast was ended due to hypoglycemia in 42.5% in 12 
hours, 66.9% by 24 hours and 94.5% in 48 hours (Hirshberg, et al. 2000). 
7.1.4 Other laboratory tests 
7.1.4.1 Intravenous secretin test for insulinoma 
In patients harboring and insulinoma, insulin production by normal pancreatic beta cells is 
significantly suppressed. Following intravenous injection of secretin (2 units/kg of body 
weight), plasma insulin rises more than 200% in normal individuals, whereas in patients 
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with insulinoma, the secretin stimulation test does not cause a rise in plasma insulin due to 
the unresponsiveness of insulinoma cells to secretin. (Imamura, M., et al. 1990) 
7.1.4.2 C-peptide inhibition test with hog insulin 
After proinsulin cleavage, insulin and c-peptide are secreted. Infusion of hog insulin for 1 
hour leads to the decrease of plasma c-peptide levels in healthy subjects, but no such 
decrease is observed in insulinoma patients. Insulin release from insulinoma cells is not 
inhibited by the administration of exogenous insulin, whereas insulin secretion from normal 
beta-cells is inhibited by the increased plasma insulin. (Service, FJ., et al. 1992) 
7.2 Diagnostic imaging 
The diagnostic suspicion of an insulinoma is based on symptoms, and laboratory techniques 
usually confirm the diagnosis. The treatment, on the other hand, is usually surgery of the 
tumoral mass as complete as possible, including the primary tumor and metastases if present. 
Imaging of the primary tumor location and the extent of the disease is needed for all phases of 
management of pancreatic neuroendocrine tumors. It is needed to determine whether the 
surgical resection for possible cure or possible cytoreductive surgery is needed and whether 
treatment for advanced metastatic disease is appropriate and during follow-up to assess the 
effects of any antitumor treatment as well as the need for deciding whether additional 
treatments are indicated. Imaging plays also a pivotal role in differentiating these tumors from 
adenocarcinomas of the pancreas. As a result, a fundamental part in the process of the 
diagnosis and treatment of an insulinoma will be the localization with imaging techniques. 
Insulinomas are often of a small size and localization may be difficult. A number of different 
imaging modalities have been widely used including conventional imaging studies (CT, 
MRI, ultrasound, angiography), endoscopic ultrasound, functional localization studies 
measuring hormonal gradients, intraoperative methods particularly intraoperative 
ultrasound and recently PET preoperatively. 
7.2.1 Abdominal ultrasound 
Abdominal ultrasound has the advantages of being a non-invasive technique, free of radiation, 
anatomically precise, low-cost and world-wide used. On the other hand, key major drawbacks 
include its dependence on the operator expertise and on the limitations based on the patient’s 
habitus that is usually unfavorable since many insulinoma patients are overweight or obese. 
Regular ultrasound investigation of the pancreas is rarely helpful in the localization of an 
insulinoma. The sensibility reported with this technique to detect insulinoma is low, about 
9%. However, it is done routinely to exclude the presence of liver metastases before surgery. 
Commonly, it is the first imaging technique to detect liver metastases and therefore leading 
to the performance of more precise techniques which detect the malign insulinoma. 
7.2.2 Endoscopic ultrasonography (EUS) of the pancreas 
EUS is a relatively new technique. It is remarkably accurate locating pancreatic 
neuroendocrine tumors, especially those located in the pancreatic tail (Figure 5). EUS 
requires the availability of expensive echoendosonographic and processing equipment. Such 
equipment is found only in large hospitals or endoscopy units. 
Most gastroenterologists now consider EUS to be the most accurate, least expensive 
preoperative method of locating neuroendocrine pancreatic tumors. The technical 
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advantage of EUS imaging over transabdominal ultrasonography is due to the close 
proximity of the transducer to the target. This permits the use of high scanning frequencies, 
which provide much greater spatial resolution. Rosch et al. prospectively compared the 
accuracy of EUS and ultrasonography, computed tomography, and endoscopic retrograde 
cholangiopancreatography in the detection of pancreatic tumors.22 The sensitivity and 
specificity of EUS in localizing pancreatic tumors is 99 and 100%, respectively, compared 
with ultrasonography (67 and 40%, respectively) and computed tomography (77 and 53%, 
respectively) and is equal to endoscopic retrograde cholangiopancreatography (sensitivity of 
90%).  
In a recent multicenter study, EUS was shown to be the most sensitive localization modality in 
accurate detection of pancreatic tumors (sensitivity of 82 versus 27%) and had a specificity of 
95%. EUS accurately defines the size of tumors to within 2 mm of the excised lesion. 
EUS is a valuable method of localizing insulinomas. The technique requires specialized 
endoscopic skill, but it is both safe and effective in experienced hands. EUS should prove to 
be very helpful for localization of insulinomas undetectable by transabdominal 
ultrasonography or computed tomography, but it is not a satisfactory method for evaluating 
the liver in patients suspected to have metastatic disease. (Andersen, A., et al, 2004) 
 
 
Fig. 5. Endoscopic ultrasonography of a bening insulinoma. The arrow points the tumoral 
mass. 
7.2.3 Computed tomography (CT)  
Although in recent years gadolinium-enhanced MR imaging, somatostatin-receptor 
imaging, and endosonography have emerged as potentially competing or complementary 
techniques to CT, dual-phase helical CT, particularly with technical improvements afforded 
by multidetector CT, remains the dominant imaging modality for the diagnosis of all 
pancreatic neoplasms, including islet cell tumors. In expert hands, helical CT can detect 
about two-thirds of the insulinomas.  
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Because of their rich vascular supply, insulinomas classically are hyperattenuating 
compared with the surrounding pancreatic parenchyma on contrast-enhanced CT. 
Capturing the vascular blush is essential for the diagnosis of small tumors, which often do 
not distort the contour of the pancreas. This is particularly true in the investigation of 
functioning insulinomas because these are often small, with 50% measuring less than 1.3 cm. 
The classic and most common enhancement pattern of islet cell tumors is that of a 
hyperattenuating lesion in the arterial and venous phases. Many small lesions enhance more 
prominently and thus are easier to detect in the arterial phase or become inconspicuous in the 
venous phase. In a series of 11 cases of functioning islet cell tumors reported by Van Hoe et al., 
most lesions were hyperattenuating and two were more conspicuous on arterial phase imaging. 
Helical CT is not only useful for the detection of the insulinoma but also in the staging of 
malignant insulinoma on dual-phase CT.  Three-dimensional CT reconstructions exquisitely 
show local extension and encasement of the major peripancreatic arteries and veins for 
surgical planning. The liver and regional lymph nodes are the most common sites for 
metastases. Like the primary tumor, liver metastases are hypervascular. Arterial phase 
images show the number and size of the hepatic lesions better than images acquired in the 
venous phase, particularly for small metastases. Spread to regional lymph nodes also is more 
conspicuous in the arterial phase. 
The reported sensitivity of CT in localizing functioning islet cell tumors varies from 71% to 
82% because small tumors are more frequently missed. Small hyperattenuating islet cell 
tumors located in the pancreatic neck or body can be confused with adjacent vascular 
structures; multiplanar reconstruction is helpful in separating the lesion from surrounding 
vessels, thus improving diagnostic confidence. (Sheth, S., et al, 2002).   
 
 
Fig. 6. CT scan of malignant insulinoma (no contrast). Hypointense solid irregular mass of 2 
x 3 cm in the tail of the pancreatic gland. Hepatomegaly with multiple metastases, solid and 
hypointense, of different sizes, the bigger one of 5.5cm. 
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7.2.4 Magnetic resonance imaging  
Recent reports have suggested an important role for MRI in the
 
detection of pancreatic NET, in 
particular with the use of fast
 
spin echo and fat saturation techniques. MRI has presented 
excellent results, its sensitivity ranges from 85-95% in the detection of insulinomas (including 
those with less than 1.5 cm in diameter) and the determination of the presence of metastases.  
Using conventional sequences, small insulinomas usually have a low signal on T1-weighted 
sequences and a high signal on T2-weighted sequences. Some insulinomas containing 
fibrous tissue may show low signal intensity on both T1 and T2 weighted images.  
An improvement in MRI techniques is the use of diffusion weighted MRI. Fat suppressed
 
T 1 
weighted sequences have been reported to be particularly
 
useful in imaging pancreatic lesions, 
especially islet cell
 
tumours. The normal pancreas is
 
of relatively high signal intensity on fat 
saturated T 1 weighted
 
images. Islet cell tumors are of lower signal intensity than
 
normal 
pancreatic tissue. This increased contrast between tumors
 
and pancreas explains the greater 
detection rate with fat suppressed
 
T 1 weighted images. (Semelka, RC., et al, 2000) 
7.2.5 Angiography and arterial stimulation of the pancreas 
Although most insulinomas are small, they have been successfully detected by computed 
tomography and magnetic resonance imaging recently. However, preoperative localization 
of the insulinomas by arterial stimulation with venous sampling is crucial when they show 
atypical findings on these imaging modalities.  
That is, it is difficult to determine whether the tumor is benign or malignant, whether it is a 
nonfunctioning tumor accompanying an extra or undetectable pancreatic insulinoma, or 
whether it is one of the multiple insulinomas. Morphological imaging modalities do not 
reflect hormonal functions; however, the addition of angiography and arterial stimulation 
helps regionalize a tumor by verifying the hormonal function. This procedure enhances a 
more accurate surgical approach in clinical exploration and can prevent a possible 
resurgery. Thus, for atypical insulinomas, preoperative localization of insulinomas by 
angiography and arterial stimulation may be particularly important. 
Mesenteric angiography is a well established invasive technique in which pancreatic 
endocrine tumors appear as a well circumscribed blush, usually four to eight seconds after 
the contrast injection. The reported sensitivity for the detection of primary tumors ranges 
between 28 and 70 percent. The accuracy for diagnosing hepatic metastases is higher 
(sensitivity 62 to 78 percent). 
Arterial stimulation venous sampling involves selective injections into arteries supplying 
the pancreas of a stimulating secretagogue. Insulin production is measured in the pancreatic 
gland by a catheterization of the main arteries (superior mesenteric artery, gastroduodenal 
artery, hepatic artery and splenic artery). Insulin secretion is stimulated by an injection in 
each of these arteries of calcium (0.025 mEq/kg) diluted in a 5 mL injection. Plasma 
extractions are done at 0, 30, 60, 90 and 120 seconds after the injection. The test is considered 
positive if there is an increase of insulin two-fold greater the basal between 30 and 120 
seconds. This technique permits de location of the tumor in the portion of the pancreas 
which is irrigated by one of these arteries. 
Results with this technique are encouraging. One report evaluated 24 patients with proven 
hyperinsulinemia. Seven of these patients had negative imaging technique and in all of them 
calcium infusion permitted localization of the source of insulin secretion. Although helpful, 
angiography and arterial stimulation is an invasive and costly technique that should be 
reserved for atypical insulinomas or when nesidioblastosis is suspected. 
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7.2.6 Scintigraphy with octeotride  
The absence of somatostatin receptors in half of insulinomas and the lack of spatial 
discrimination with nuclear scanning are detractions to the routine use of this new 
localization test. 
In addition, scintigraphic
 
imaging with Octreoscan has been introduced in an attempt to
 
improve topographic assessment of insulinomas. The results were
 
disappointing, since 
Octreoscan scintigraphy with planar imaging
 
led to detection of only 20–50% of insulinomas  
7.2.7 Positron emission tomography PET 
The results of 18-fluordeoxyglucose (18-FDG) PET imaging for insulinomas are not very 
promising, maybe due to the low proliferative potential of these tumor cells. Positive results 
have been shown using 11 C-5-hydroxi-L-tryptophan, 18-3, 4-Dihydroxy-6-fluoro-DL-
phenylalanine and 67-Ga-DOTA-DPhe 1-Tyr 3-octeotride due to selective uptake in tumor 
tissue compared to surrounding tissue. These techniques produce very good tumor visibility 
and can be used for the examination of both the thorax and abdomen. However, the lack of 
general availability of PET scanning and high cost, limits its use. 
7.2.8 PET/TC 
The 18-fluorine-18-fluoro-2-deoxyglucose Positron Emission Tomography coupled with 
computed tomography is a non invasive exploration. Several studies have shown that PET-
CT has superior efficacy over conventional imaging techniques in distinguishing a benign 
pancreatic tumor from a malignant one. It contributes to the diagnosis of cancer in patients 
with a doubtful mass, much more in case of chronic pancreatitis. 
7.2.9 Intraoperative localization techniques 
Intraoperative ultrasonography allows high resolution examination of the pancreas. When 
combined with palpation of the organ, the sensitivity for tumor detection ranges 83 to 100 
percent. Intraoperative transillumination has equivalent efficacy (sensitivity of 83 percent). 
Neither of these tests should replace preoperative imaging; they are used as adjuncts to 
intraoperative palpation. (Figure 7) 
Diagnostic algorithm for insulinomas 
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8. Staging of insulinoma tumors 
After the performance of imaging techniques, insulinomas which are the most frequent 
neuroendocrine pancreatic tumors, must be classified.  The classification proposed by AJCC 
(American Joint Committee on Cancer) ENETS (European Neuroendocrine Tumor Society) 
for neuroendocrine pancreatic tumors is the following (Table 4): 
 
 
Table 4. Staging of TNEs of the pancreas according to AJCC and ENETs 
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The WHO has an alternative classification and staging for pancreatic neuroendocrine 
tumors, which considers also certain anatomopathological findings. The proliferative rate 
has been repeatedly shown to provide significant prognostic infromation for NETs. The 
proliferatice rate can be assessed as the number of mitosis per unit area of tumor (usually 
expressed as mitosis per 10 high power microscopic fields or 2mm) or as the percentage of 
neoplastic cells immunolabeling for the proliferation marker Ki-67.  The use between mitotic 
count and Ki-67 is controversial. When the amount of tumor tissue is limited, it may not be 
able to perform an accurate mitotic count. In these cases Ki 67 staining provides a more 
accurate assessment of proliferative rate, and it is particularly helpful to separate well-
differentiated tumors from poorly differentiated neuroendocrine carcinomas, which usually 
have dramatically different Ki 67 labelling rates. However, when adequate tissue is present 
to perform an accurate mitotic count, there are no data to demonstrate that the Ki67 labeling 
index adds important information, and in some cases, the two measures of proliferative rate 
may provide conflicting information about grading.(Table 5) 
 
Grade 
(WHO) 
Biological 
behavior 
M1 Histology 
Angio 
invasion
Primary 
tumor 
(cm) 
Ki-
67% 
Mitotic 
count 
1 Benign - 
Good 
differentiation
- < 2 <2 <2 
1 Undefined - 
Good 
differentiation
+/- >2 2-5 <2 
2 
Malignancy 
low grade 
+ 
Good 
differentiation
+ >3 5-15 2-10 
3 
Malignancy 
high grade 
+ 
Poor 
differentiation
+ whatever >15 >10 
Table 5. WHO staging for pancreatic neuroendocrine tumors 
9. Medical management of insulinoma related to hormone hypersecretion 
Benign insulinomas, as well as malignant, usually produce high concentrations of insulin 
secretion developing the well-known hypoglycemic syndrome. Independently of their 
surgical possibilities, hypoglycemia must be controlled. 
With insulinomas, dietary modification with frequent small feedings may help control 
hypoglycemia. Sometimes endovenous glucose infusion may be needed to maintain 
acceptable glucose levels usually in the preopreatory or when it is a high secreting 
malignant insulinoma. Glucose infusion must be done with care as patients may develop in 
rare cases acidosis secondary to large volumes of glucose infusion (Ramos,A., et al., 2010). 
When diet modification does not control the symptoms, pharmacological treatment must be 
used. There are several pharmacological treatments the most frequently used is diazoxide 
followed by somatostatin analogues. (Hirshberg, B., et al 2005) 
9.1 Diazoxide 
Administration of diazoxide (200-600 mg/day) successfully controls hypoglycemia in 50 to 
60 % of the patients. The most common side effect reported with diazoxide is hirsutism as 
well as nausea at higher dose administration. Also, diazoxide frequently leads to fluid 
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retention requiring diuretics such as triclormetiazide which not only counteracts this side-
effect but has also a hyperglycemic effect. 
Diazoxide enables the control of the hypoglycemia by two mechanisms: it inhibits insulin 
secretion by beta-cell pancreatic cells and it has a peripheral effect stimulating 
glucogenolisis. Treatment with diazoxide has proven to be efficient, including cases with 
nesidioblastosis in which surgery seemed to be a very radical option. In advanced metastatic 
disease in which surgery is not an option, diazoxide has demonstrated in some studies to be 
more effective in the symptomatic control at short-time. 
9.2 Calcium antagonists and others 
Calcium antagonists may also be useful controlling hypoglycemia because they inhibit 
insulin secretion by the blockage of the calcium receptor. There are some works on 
advanced metastatic disease that describe a better symptomatic control with verapamil 
added to the long-acting somatostatin analogues. On the other hand, the data of their use is 
limited, therefore limiting their use to cases with advanced disease in which other 
treatments are uneffective. 
Other options to control hypoglycemia may be beta blockers, that can be useful, although 
they might be used with precaution as they can mask hypoglycemia symptoms. Other 
pharmacological treatments include phenytoin or glucagon. Glucocorticoids increase 
gluconeogenesis and create insulin resistance, so they can also be useful. The recommended 
dose is of 1mg/kg of prednisone. 
9.3 Somatostatin analogues 
Long-acting somatostatin analogues have proved to be a novel and very useful treatment in 
the control of hypoglycemia.  
Lately the presence of somatostatin in pancreas islets and other areas of the digestive tract, 
as well as its inhibitory effect of the secretion of other hormones, such as insulin, its role as 
neurotransmisor or neuromodulator and cytostatic effect have been recognized. 
Somatostatin was therefore considered as a possible treatment for those endocrinological 
syndromes caused by excess hormone production. However, human somatostatin has a 
very short half-life effect, which made the development of what today we know as the long-
acting somatostatin analogues. 
Their main indication is in the preoperatory phase, or in cases of recurrence and malignancy. 
Also, although it is not their main indication, cases of complete resolution in benign 
insulinomas have been reported. These analogues function predominantly over subtype 2 
somatostatin receptor and less over subtype 5, controlling therefore about 50% of the 
hypoglycemic events caused by insulinomas. The somatostatin subtype 5 receptor has been 
involved in insulin secretion and seems to be related with a more aggressive tumoral behavior.  
New somatostatin analogues are being developed with a greater affinity to this and other 
receptors such as BIM23244 and SOM230.An important aspect before starting the treatment of 
an insulinoma with somatostatin analogues is to analyze the possible efficacy by the 
performance of an Octreoscan or by demonstrating an improvement on glucose and insulin 
levels with short-acting somatostatin analogues. This is important because their use in tumors 
which do not  express subtype 2 may worse the hypoglycemia by the inhibition of the 
contrarregulatory response of glucagon and growth hormone without affecting insulin 
secretion. Another possible problem when long-acting somatostatin analogues are used long-
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term, is a desensibilization of the tumor by a decrease in the expression of the 
somatostatinreceptors. Initially this can be overwhelmed by increasing the dose of the 
analogue or decreasing the interval administration, but can cause at the end a therapeutic fail.  
9.4 New agents to control hypoglycemia 
Recent studies in small numbers of patients show that mTOR inhibitors, such as rapamycin 
or everolimus, may control hypoglycemia in patients with metastasic insulinomas.  
Everolimus is an orally derivative of rapamycin that inhibits Ser/Thyrosine kinase mTOR. 
The PI3k/Akt/mTOR pathway has an important role in pancreatic cancer biology. It has 
demonstrated to have an antitumor activity, but its effects on pancreatic beta cells remains 
unclear. Data suggest that functional insulin receptors are present on beta cells and mediate 
insulin stimulated insulin production and release and that mTOR inhibition downstream of 
insulin receptors may decrease insulin production and release. It is also possible that 
everolimus induces insulin resistance peripherically. 
Recent case series have reported malignant insulinomas with severe hypoglycemic 
syndrome who were able to cease, or significantly reduce symptoms after the introduction 
of everolimus.  
 
MEDICAL THERAPY FOR 
UNCONTROLLED HYPOGLYCEMIA 
 
DRUG CLASS 
SYMPTOM 
CONTROL 
ADVERSE EFFECTS 
Diazoxide 
Alpha adrenergic 
agonist 
50-60% of patients 
 
peripheral edema, 
nausea, hirsutism 
Octeotride Somatostatin analog 
40-60% of patients 
 
bloating, abdominal 
cramping, 
malabsorption, 
cholelithiasis 
Verapamil 
Calcium channel 
blocker 
unknown 
 
constipation, peripheral 
edema, nausea 
Propranolol Beta-blocker 
unknown 
 
bradycardia, depression, 
may potentiate 
hypoglycemia 
Phenytoin Anticonvulsivant 
unknown 
 
hypertrichosis, gingival, 
hypertrophy, peripheral 
neuropathy 
Prednisone Glucocorticoids unknown Cushingsyndrome 
Glucagon Glucagon palliation 
risk of rebound 
hypoglycemia 
Table 6. Medical Therapy for Uncontrolled hypoglycemia 
10. Surgical treatment of benign insulinoma or primary tumor  
All experts agree that surgical resection of an insulinoma either benign or malignant should 
be considered whenever possible. Local resection or enucleation of the insulinoma is 
generally recommended, and more advanced surgical resections such as Whipple resections 
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are not routinely recommended and should be considered only in carefully selected 
patients. (Figure 7 and 8) 
Generally pancreatic neuroendocrine tumors are surgically approached by a laparotomy to 
allow an extensive exploration of the entire abdomen and search for lymph node metastases. 
Insulinomas in non-MEN 1 with benign characteristics are increasingly being treated with a 
laparoscopic approach; in 85% of patients, there are single tumors, they are invariably 
intrapancreatic, and if they can be localized preoperatively, they can be cured in 70% to 
100% using laparoscopic approach. At the present surgical cure rates for benign insulinomas 
approach 100%. 
 
 
 
 
Fig. 7. Bening insulinoma. .Upper image:. Intraoperatory ultrasonography. .Lower image:. 
Enucleation of the same tumoral mass. 
When clinical examinations including angiography stimulation suggest nesidioblastosis, a 
partial pancreatectomy is usually performed. Even if a frozen biopsy confirms the diagnosis 
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of nesidioblastosis, the extent of pancreatic resection remains questionable. A distal 
pancreatectomy which can control the symptoms of the majority of patients, is well 
tolerated, and does not induce endocrine or exocrine insufficiency. Recovery after a partial 
pancreatectomy can remove enough abnormal proliferative tissue to achieve 
normoglycemia. However, some investigators recommend an initial near-total 
pancreatectomy. Such extensive resections lead to an increased risk of post-surgical diabetes 
and pancreatic insufficiency. It seems that the best recommendation is a 70%-80% 
pancreatectomy, administration of diazoxide when hypoglycemia persists post-operatively, 
and a more extensive resection when previous measures fail. 
 
BENIGN 
INSULINOMA
LOCOREGIONAL 
DISEASE
Stabilize 
glucose 
levels:
-diet
-glucose ev
- diazoxide
- somatostatin
analogues
Tumor enucleation
Consider laparoscopic resection
or
Subtotal pancreatectomy
or
Pancreatectoduodenectomy
or 
Distal pancreatectomy (spleen 
preserving)
 
Fig. 8. Therapeutical algorithm for benign insulinoma or primary located disease 
11. Additional management in advanced insulinomas 
Malignant insulinomas, although unfrequent, may require multiple managements involving 
a mutidisciplinar follow-up. Firstly hypoglycemic syndrome must be adequately controlled. 
Secondly, surgical approach must be used if possible, to control metastasic and primary 
disease. When curative surgery is not possible, usually due to metastasic disease, debulking 
surgery is often a beneficial treatment for local (intestinal obstructions, etc.) and endocrine 
symptoms. On the other hand, when the disease is extended and surgical approach is not 
possible, other therapeutic options can be used depending on the organ affected.(Figure 9 
and 10). 
11.1 Surgical approach of metastasic disease 
Hepatic resection is indicated for the treatment of metastasic liver disease in the absence of 
diffuse bilobar involvement, compromised liver function or extensive extrahepatic 
metastases. 
However, the role of cytoreductive surgery in these cases is controversial. Whereas 
numerous uncontrolled studies provide evidence that surgical resection may improve 
symptom control and perhaps extend survival, neither result is proven at the present. 
Nevertheless, because of the low efficacies of other tumor treatments, most conclude that 
surgical resection should be attempted in any patient with a malignant insulinoma if it is 
thought that at least 90% of the visible tumor could be removed. Unfortunately, surgical 
resection of at least 90% of all visible tumor is possible only in 5% to 15% of patients with 
insulinoma and metastasic disease. 
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Fig. 9. Metastasic disease of insulinoma.Upper image: single hepatic metastases. Lower 
image: multiple hepatic metastases. 
Transplantation for metastasic disease has been proposed for the occasional, younger 
patient with a metastasic insulinoma that is unresectable and limited to the liver, especially 
if it is symptomatic and cannot be controlled by other available therapies, that liver 
transplantation remains an option that should be considered.  
11.2 Other invasive therapies 
Hepatic artery embolization is recommended as a palliative option in patients with hepatic 
metastases who are not candidates for surgical resection, have an otherwise preserved 
performance status, have disease primarily confined to the liver, and have a patent portal 
vein. The response rates associated with embolizations, as measured either by decrease in 
hormonal secretion or by radiographic regression are generally greater than 50%. Improved 
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techniques have, in recent years, reduced the incidence complications related to 
embolization, making embolization an important and generally safe treatment. A number of 
techniques can be used and include bland embolization, chemoembolization, embolization 
with chemotherapy and embolization using radioisotopes. These techniques should be 
considered especially for a patient with a functional secreting insulinoma in which the 
hormone excess cannot be controlled by other methods. (O’Toole, D., et al 2005) 
Other approaches to the treatment of hepatic metastases in a patient with malignant 
insulinoma include the use of radiofrequency and crioablation, either alone or in conjuction 
with cytoreductive surgery. These approaches can be performed using a percutaneous or 
laparoscopic approach. Although they seem to be less morbid than either hepatic resection 
or hepatic artery embolization, the clinical benefit of these approaches in patients with 
asymptomatic, small volume disease has not been clearly established. Similarly, these 
approaches may not be applicable in patients with large-volume hepatic metastases. 
Ablative techniques should therefore be considered as a treatment option only in carefully 
selected patients. (Steinmuller, T., et al 2008) 
Peptide receptor radionuclide therapy can be an option in those pancreatic tumors which 
have an overexpression of somatostatin receptors. This expression is not frequent within 
insulinomas.  
11.3 Radiotherapy 
Experience with external beam radiotherapy in the management if islet tumor cells is 
limited. Although pancreatic neuroendocrine carcinomas were previously considered to be 
radioresistant, data from published case reports and small case series suggest that 
radiotherapy can produce high rates of symptom palliation and freedom from local 
progression in patients who are not candidates for surgical resection. There are no specifical 
data on the rate of symptom control in patients with symptomatic insulinomas.  
However, radiotherapy with or without biphosphonates has proven to be highly useful in 
patients with painful bony metastases. 
11.4 Traditional chemotherapeutic agents  
A number of chemotherapeutic agents either alone or in combination have been reported to 
have sufficient antitumor activity to be clinically useful. Systemic chemotherapy is 
recommended for patients with unresectable liver or lung metastases. Trials using 
chemotherapeutic drugs including doxorubicin, streptoxocin, 5-FU, temozolamide, and 
dacarbazine have established cytotoxic effects in pancreatic tumors. The combination of 
doxorubicin and streptozocin has a reported 69% objective response rate in the treatment of 
patients with advances islet cell carcinoma. A retrospective review from the MD Anderson 
Center reported an objective response rate of 39% with the combination of 5FU, doxorubicin 
and streptozocin. Fine et al have reported on the synergy between capecitabine and 
temozolamide for the induction of apoptosis in neuroendocrine cell lines. Recently, an oral 
regimen using temozolamide and thalidomide was found to be useful in a number of 
neuroendocrine malignancies. (Kouvaraki, M., et al. 2004) 
11.5 Newer agents 
11.5.1 Biotherapy: Somatostatin analogues and interferon 
Somatostatin analogues have a double purpose in the treatment of insulinomas, firstly they 
can control hypoglycemia and secondly they are used in those patients with advanced 
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disease for their possible effect on tumor growth. The clinical benefit of the direct antineoplasic 
effects of somatostatin analogues either with or without interferon remains uncertain, 
although recent studies suggest they have a cytostatic effect in 40 to 70% of patients and cause 
a tumor reduction of less than 15% with both agents. This tumoristatic effect can be long 
lasting especially in those with low proliferative rate. (Plockinger, U., et al. 2007) 
11.5.2 Anti-angiogenic treatments 
Recent studies using vascular endothelial growth factor (VEGF) pathway inhibitors such as 
bevacizumab have suggested that these agents may have a modest antitumor activity in 
patients with malignant pancreatic tumors. Actually there are several active studies 
combining chemotherapy and bevacizumab in adavanced pancreatic NETs. However the 
recruited patients are small, and for the moment there are no specifical results for malignant 
insulinomas.  
Sunitinib inhibits celular signaling by targeting multiple receptor tyrosine kinases. These 
include all receptors for platelet-derived growth factor (PDGF-Rs) and VEGF receptors, which 
play a role in both tumor angiogenesis and tumor cell proliferation. The simultaneous 
inhibition of these targets therefore leads to both reduced tumor vascularization and cancer 
cell death, and ultimately tumor shrinkage. In phase 1 and 2 trials, sunitinib showed antitumor 
activity in patients with pancreatic neuroendocrine tumors. A phase 3 has been recently 
conducted in well-differentiated pancretic neuroendocrine tumors in which the results were 
promising causing a discontinuation of the study. Median progression-free survival was 11.4 
months in the sunitinib group as compared with 5.5 months in the placebo group (hazard ratio 
for progression or death, 0.42; 95% confidence interval [CI], 0.26 to 0.66; P<0.001). There are no  
results for the moment specifical in malignant insulinomas. (Raymond, E., et al 2011) 
11.5.3 Inhibiton of m-TOR 
Everolimus, an inhibitor of mTOR has also being study recently not only from the 
antihipoglycemic but also from the antitumoral point of view. Its efficacy has been studied 
combined with somatostatin analogues in neuroendocrine tumors. Considering 
insulinomas, the mean survival without progression was estimated in 63 weeks. (Yao et al., 
2008). Considering other studies with pancreatic NETs in general, everolimus (at a dose of 
10 mg/day) caused a 65% reduction in the estimated risk of progression (progression-free 
survival of 11 months with everolimus versus 4.6 months with placebo, p< 0.001). 
Confirmatory studies of these promising results are being performed. 
12. Posttreatment surveillance 
After the complete removal of the tumor, a patient with a benign insulinoma is cured, but 
periodic follow-up is necessary in those with metastasic insulinoma or multiple endocrine 
neoplasia type 1 (MEN1). 
12.1 MEN 1 
All patients with MEN 1 syndrome should be followed with every 3-6 months during the 
first year after resection with physical examination, tumoral markers and calcium levels as 
appropriate and with imaging studies such as CT/MRI. The follow-up tests must be 
repeated every 6 months, 1-3 years after surgery and annually thereafter.  
All close family members of patients with MEN 1 should be genetically counseled and 
genetic testing should be considered. 
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Fig. 10. Therapeutic algorithm of malignant insulinoma. Adapted from National 
Comprehensive Cancer Network, 2010. 
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12.2 Malignant insulinoma 
There are no evidence-based guidelines for follow-up after resection of a malignant 
insulinoma. Consensus derived guidelines from the National Cancer Network following 
treatment of an islet cell tumor include the following: 
- Three and six months postresection: history and physical examination, tumor markers 
(insulin) and CT/MRI. 
- Long-term: history and physical examination with tumor markers every 6-12 months 
for years 1 to 3. Imaging studies are recommended only if clinically indicated. 
13. Conclusions 
Pancreatic beta cell tumors are a relatively rare cause of hypoglycemia. The suspicion of a 
probable insulinoma by the physician is important as the diagnosis of these tumors may be 
delayed up to 1-2 years and may be confused with other diseases such as neurological or 
psychiatric. 
The diagnostic suspicion of an insulinoma is based on symptoms, and laboratory techniques 
usually confirm the diagnosis. The treatment, on the other hand, is usually surgery of the 
tumoral mass as complete as possible, including the primary tumor and metastases if 
present and possible. Imaging of the primary tumor location and the extent of the disease is 
needed for all phases of management of insulinomas, especially if they are malignant. 
The development of new treatments based upon a better knowledge of the molecular 
pathways involved in tumorigenesis make the therapeutic future of these tumors promising, 
leading to a better prognosis in those with a more aggressive behavior. 
On the other hand, the low incidence of these tumors makes especially important their 
management in specialized centers with experience and modern imaging and diagnostic 
techniques. 
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